Observational studyEuropean journal of clinical pharmacology2026
The phenprocoumon echo: Elevated INR risk after VKA reversal - A retrospective analysis of phenprocoumon and acenocoumarol in clinical practice in a Dutch teaching hospital.
Observational study in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn case of excessively elevated INR values (INR > 6), major bleeding or emergency surgery, there is a need to reverse the anticoagulant effect of vitamin K antagonists (VKAs). Phenprocoumon’s longer half-life poses greater challenges for reversal compared to acenocoumarol when using short-acting agents like phytomenadione and prothrombin complex concentrate (PCC). Data on supratherapeutic INR recurrence after reversal of both acenocoumarol and phenprocoumon remain limited. This study aims to compare the incidence of supratherapeutic INR following reversal with PCC and/or phytomenadione in patients using phenprocoumon versus acenocoumarol.
methodsA retrospective observational study was conducted at Spaarne Gasthuis (Haarlem/ Hoofddorp, the Netherlands), analysing data from 2009 to 2024. Patients using acenocoumarol or phenprocoumon who achieved successful reversal (INR ≤ 2.0 within 48 h) with PCC and/or phytomenadione were included. Patients were followed from 48 h post-reversal until INR > 3.5, VKA resumption, discharge, death, or 14 days post-reversal. The primary outcome was the time to elevated INR (> 3.5).
resultsA total of 2,334 admissions were included. In 1,506 admissions, no INR was measured during follow-up. Phenprocoumon use was associated with a significantly higher risk of supratherapeutic INR after both PCC-based reversal (HR: 4.01, 95% CI: 1.41–15.30) and phytomenadione alone (HR: 3.71, 95% CI: 1.20-14.72). The risk was especially pronounced in patients with a baseline INR ≥ 6.
conclusionPhenprocoumon use is associated with a higher risk of supratherapeutic INR elevation following reversal compared to acenocoumarol use. In patients with a baseline INR ≥ 6, almost all recurrences were in phenprocoumon users.
Indexed as
Identifiers
41649572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.